Neuroendocrine regulation of natural immunity

NeuroImmune Biology

Volumn 5, Issue C, 2005, Pages 215-262

  Berczi, Istvan ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957836192     PISSN: 15677443     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-7443(05)80017-1     Document Type: Chapter

References (478)

1. th edition (2001), Garlnad Publishing, New York 35-91
2. Bertok L. Stimulation of nonspecific resitance by radio-detoxified endotoxin. In: Nowotny A. (Ed). Beneficial effects of endotoxins. (1983), Plenum Press, New York 213-226
3. Berezi J. Neuroendocrine defence in endotoxin shock. Acta Microbiol. Hung. 40 (1993) 265-302
4. Sabbadini E.R., and Berczi I. The submandibular gland: a key organ in the neuroimmunoregulatory network?. Neuroimmunomodulation 2 (1985) 184-202
5. Berczi I. Neurohormonal host defence in endotoxin shock. Ann NY Acad Sci 840 (1998) 787-802
6. Berczi I., and Nagy E. Neurohomonal control of cytokines during injury. In: Rothwell N.J., and Berkenbosch F. (Eds). Brain control of the response to injury (1995), Cambridge University Press 32-107
7. Medzhitov R., and Janeway C.A. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9 (1997) 4-9
8. Boismenu R., and Havran W.L. An innate view of γδT cells. Curr. Opin. Immunol. 9 (1997) 57-63
9. Berczi I., Chow D.A., and Sabbadini E.R. Neuroimmunoregulation and natural immunity. Domestic Animal Endocrin 15 (1998) 273-281
10. Bereri I., Bertok L., and Chow D.A. Natural immunity and neuroimmune host defence. Ann NY Acad Sci 917 (2001) 248-257
11. rd Edition (1975), Year Book, Chicago
12. Nagy E., Berezi I., and Friesen H.G. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol 102 (1983) 351-357
13. Berezi I., and Nagy E. Human placental lactogen is a hemopoeitic hormone. Brit J Haematol 79 (1991) 355-358
14. Nickel B.F., Kardami E., and Cattini P.A. The human placental growth hormone variant is mitogenic for rat lymphoma Nb2 cells. Endocrinology 126 (1990) 971-976
15. Moreno J., Vicente A., Heijnen J., and Zapata A.G. Prolactin and early T-cell development in embryonic chicken. Immunol Today 15 (1994) 524-526
16. Crilly P.R., Johnson P.C., Gardner M.J., and Flint D.J. Immunoneutralisation of GH in neonatal rats results in defects in lymphatic tissues and the humoral immune response. Endocrine J 2 (1994) 105-109
17. Crafts R.C., and Meinecke H.A. The anemia of hypophysectomized animals. Ann NY Acad Sci 77 (1959) 501-517
18. Jepson J.H., and Lowenstein L. The effect of testosterone adrenal steroids and prolactin on erythropoiesis. Acta Haematol 38 (1967) 292-299
19. Berezi I., and Nagy E. The effect of prolactin and growth hormone on hemolyphopoietic tissue and immune function. In: Berezi I., and Kovacs K. (Eds). Hormones and Immunity (1987), MTP Press, lancaster England 145-171
20. Nagy E., and Berezi I. Pituitary dependence of bone marrow function. Brit J Haematol 71 (1989) 457-462
21. Berezi I., Nagy E., DeToledo S.M., Matusik R.J., and Friesen H.G. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J Immunol 146 (1991) 2201-2206
22. Murphy W.J., Durum S.K., Anver M.R., and Longo D.L. Immunologic and hematologic effects of neuroendocrine hormones. J Immunol 148 (1992) 3799-3805
23. Dogusan Z., Book M.L., Verdood P., Yu-Lee L.Y., and Hooghe-Peters F.L. Prolactin activates interferon regulatory factor-I expression in normal lympho-hemopoietic cells. Eur Cytokine Netw 11 (2000) 435-442
24. Morales P, Carretero MV, Geronimo H, Copin SG, Gaspar ML. Marcos MA.
25. Richards S.M., and Murphy W. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J. Neuroimmunol. 109 (2000) 56-62
26. Bellone G., Geuna M., and Carbone A. Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. J Cell Physiol 163 (1995) 221-231
27. Guicheux J., Heymann D., Gouin F., Pilet P., Faivre A., and Daculsi G. Growth hormone stimulates multinucleated cell formation in long-term bone marrow cultures. Eur J Cell Biol (1998) 7559-7565
28. Merchav S., Tatarsky I., and Hochberg Z. Enhancement of erythropoiesis in vitro by human growth hormone is mediated by insulin-like growth factor-I. Brit J Haematol 70 (1988) 267-271
29. Bhat G., Gupta S.K., and Maiti B.R. Influence of prolactin on mitogenic activity of the bursa of Fabricius of the chick. Gen Comp Endocrinol 52 (1983) 452-455
30. Skwarlo-Sonta K., Sotowaska-Brochocka J., and Rosolowska-Huszez D. Effect of protactin on the diurnal changes in immune parameters and plasma corticosterone in white leghorn chickens. Acta Endocrinol 116 (1987) 172-178
31. Fraenkel-Conral H., and Li C.H. Hormonal effects on the nucleic acid and phospholipid turnover of rat liver and thymus. Endocrinology 44 (1949) 487-491
32. Baroni C.D., Fabris N., and Bertoli G. Effects of hormones on development and function of lymphoid tissues: Synergistic action of thyroxin and somatotropic hormone in pituitary dwarf mice. Immunology 17 (1969) 303-314
33. Baroni C.D., Pesando P.C., and Bertoli G. Effects of hormones on development and function of lymphoid tissues II: Delayed development of immunological capacity in pituitary dwarf mice. Immunology 21 (1971) 455-461
34. Pandian M.R., and Talwar G.P. Effect of growth hormone on the metabolism of thymus and on the immune response against sheep erythrocytes. J Exp Med 134 (1971) 1095-1113
35. 3 pituitary adenoma cells can reverse thymic aging in rats. Proc Natl Acad Sci USA 83 (1986) 5663-5667
36. Berezi I. Pituitary Function and Immunity (1986), CRC Press, Boca Raton, Florida
37. Timsit J., Savino W., and Safich B. Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells. J Clin Endocrinol Metab 75 (1992) 183-188
38. Savino W., Mello-Coelho V., and Dardenne M. Neuroendocrine control of the thymic microenvironment: role of pituitary hormones. In: Berczi I., and Szelenyi J. (Eds). Advances in Psychoneuroimmunology (1994), Plenum Press, New York 75-82
39. Yamada M., Hato F., and Kinoshita Y. The indirect participation of growth hormone in the thymocyte proliferation system. Cell Mol Biol Noisy le Grand 40 (1994) 111-121
40. Taub D.D., Tsarfaty G., and Lloyd A.R. Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment. J Clin Invest 94 (1994) 293-300
41. Esquifino A.I., Vallanua M.A., Szary A., Yau J., and Bartke A. Ectopic pituitary transplants restore immunocompetence in Ames dwarf mice. Acta Endocrinol 125 (1991) 67-72
42. Singh U., and Owen J.J.T. Studies on the maturation of the thymus stem cells: The effects of catecholamines, histamines and peptide homones on the expression of T cell alfoantigens. Eur J Immunol 6 (1976) 59-62
43. Russell D.H., Mills K.T., Talamantes R.J., and Bern H.A. Neonatal administration of prolactin antiserum alters the developmental pattern of T- and B-lymphocytes in the thymus and spleen of BALB/c female mice. Proc Natl Acad Sci USA 85 (1988) 7404-7407
44. Arezzini C., DeGori V., Tarli P., and Neri P. Weight increase of body and lymphatic tissues in dwarf mice treated with human chorionic somatomammotropin (HCS). Proc Soc Exp Biol Med 141 (1972) 98-100
45. Perez Castro C., Penalva R., Paez Pereda M., Renner U., Reul J.M., Stalla G.K., Holsboer F., and Arzt E. Early activation of thyrotropin-releasing-hormone and prolactin plays a critical role during a T cell-dependent immune response. Endocrinology 140 (1999) 690-697
46. Bernton E.W., Meltzer M.T., and Holaday J.W. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science 239 (1988) 401-404
47. Matera L., Cesano A., Bellone G., and Oberholtzer E. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B and NK lymphocytes. Brain Behav Immun 6 (1992) 409-417
48. Athreya B.H., Pletcher J., and Zulian F. Subset-specitic effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin Immunol Immunopathol 66 (1993) 201-211
49. Matera L., Contarini M., Bellone G., Forno B., and Biglino A. Up-modulation of interferon-γ mediates the enhancement of spontaneous cytotoxicity in prolactin-activated natural killer cells. Immunology 98 (1999) 386-392
50. Matera J., Cesano A., Muccioli G., and Veglia F. Modulatory effect of prolactin on the DNA synthesis rate and NK activity of large granular lymphocytes. Int J Neurosci 51 (1990) 265-267
51. Cesano A., Oberholtzer E., and Contarini M. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacology 28 (1994) 67-75
52. Majunder B., Biswas R., and Chattopadhyay U. Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12. Int J Cancer 97 (2002) 493-500
53. Rogen-Westerlaken C., Rijkers G.T., and Scholtens F.J. Immunologic studies in Turner syndrome before and during treatment with growth hormone. J Pediat 119 (1991) 268-272
54. Crist D.M., Peake G.T., and Mackinnon L.T. Exogenous growth hormone treatment alters body composition and increases natural killer cell activity in women with impaired endogenous growth hormone secretion. Metabolism 36 (1987) 1115-1117
55. Crist D.M., and Kraner J.C. Supplemental growth hormone increases the tumor cytotoxic activity of natural killer cells in healthy adults with normal growth hormone secretion. Metabolism 39 (1990) 1320-1324
56. Bidlingmaier M., Auernhammer C.J., Feldmeier H., and Strasburger C.J. Effects of growth hormone and insulin-like growth factor I binding to natural killer cells. Acta Paediatr Suppl 423 (1997) 80-81
57. 2 . J Immunol 154 (1995) 1909-1918
58. Rovensky J., Ferencikova J., and Vigas M. Effect of growth hormone on the activity of some lysosomal enzymes in neutrophilic polymorphonuclear leukocytes of hypopituitary dwarfs. Int J Tissue React 7 (1985) 153-159
59. Wiedermann C.J., Niedermuhlbicher M., and Geissler D. Priming of normal human neurophils by recombinant human growth hormone. Brif J. Haematol 78 (1991) 19-22
60. Matsuda T., Saito H., Inoue T., Fukatsu K., Han I., Furukawa S., Ikeda S., and Muto T. Growth hormone inhibits apoptosis and up-regulates reactive oxygen intermediates production by human polymorphonuclear neutrophils. J Parenter Enteral Nutr 22 (1998) 368-374
61. Fu Y.K., Arkins S., and Li Y.M. Reduction in superoxide anion secretion and bactericidal activity of neutrophils from aged rats: reversal by the combination of gamma interferon and growth hormone. Infect Immun 62 (1994) 1-8
62. Manfredi R., Turnietto F., and Azzaroli L. Growth hormone (GH) and the immune system: imparied phagocytic function in children with idiopathic GH deficiency is corrected by treatment with biosynthetic GH. J Pediat Endocrinol 7 (1994) 245-251
63. Cecilia-Fornari M., Fernanda-Palacios M., Diez R.A., and Intebi A.D. Decreased chemotaxis of neutrophils in acromegaly and hyperprolactinemia. Eur J Endocrinol 130 (1994) 463-468
64. Chen H.T., Schuler L.A., and Schultz R.D. Growth hormone receptor and regulation of gene expression in fetal lymphoid cells. Mol Cell Endocrinol 137 (1998) 21-29
65. Rapaport R., Oleske J., and Abdieh H. Suppression of immune function in growth hormone deficient children during treatment with human growth hormone. J Pediat 109 (1986) 434-439
66. Cesario T.C., Yousefi S., and Carandang G. Enhanced yields of gamma interferon in prolactin treated human peripheral blood mononuclear cells. Proc Soc Exp Biol Med 205 (1994) 89-95
67. Thellin O., Coumans B., Devos S., Hooghe-Peters E.L., Zorzi W., Igout A., Heinen E., and Hooghe R. Limited effects of placental and pituitary growth hormone on cytokine expression in vitro. Eur Cytokine Netw 11 (2000) 452-455
68. Galdiero M., Donnarumma G., Cipollareo de L'Ero G., Marcatili A., Scarfogliero P., and Sommesse I. Effect of growth hormone, prolactin and insulin on the release of the IL-1 alpha, IFN-gamma and IL-4 by staphylococcal enterotoxin A-stimulated splenocytes. Euro Cytokine Netw 6 (1995) 187-194
69. Edwards C.K., Ghiasuddin S.M., and Yunger L.M. In vitro administration of recombinant growth hormone or gamma-interferon activates macrophages: Enhanced resistance to experimental Salmonella-typhimurium infection is correlated with generation of reactive oxygen intermediates. Infec Immun 60 (1992) 2514-2521
70. Kelley K.W., Arkins S., and Li Y.M. Growth hormone, prolactin and insulin-like growth factors: New jobs for old players. Brain Behav Immun 6 (1992) 317-326
71. Horseman N.D., and Yu-Lee L.Y. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin and hematopoietic cytokines. Endocrine Rev 15 (1994) 627-649
72. Galdiero M., Vitiello M., Scarfoglicro P., and Sommesc L. Growth hormone release of interleukin-1 alpha, interferon-gamma and, interleukin-4 from murine splenocytes stimulated with staphylococcal protein A, toxic shock syndrome toxin-1 and streptococcal lysin S. Eur Cytokine Netw 8 (1997) 83-90
73. Zarkesh-Esfahani S.H., Kolstad O., Metcalfe R.A., Watson P.F., von Laue S., Walters S., Revhaug A., Weetman A.P., and Ross R.J. High-dose growth hormone does not affect proinflammatory cytokine (tumor necrosis factor-alpha, interleukin-6, and interferon-gamma) release from activated peripheral blood mononuclear cells or after minimal to moderate surgical stress. J Clin Endocrinol Metab 85 (2000) 3383-3390
74. Corbacho A.M., Nava G., Eiserich J.P., Noris G., Macotela Y., Struman J., Martinez De La Dardenne M., Mello-Coelho V., Gagnerault M.C., and Postel-Vinay M.C. Growth hormone receptors and immunocompetent cells. Ann NY Acad Sci 840 (1998) 510-517
75. Bouchard B., Ormandy C.J., Di Santo J.P., and Kelly P.A. Immune system development and function in prolactin receptor-deficient mice. J Immunol 163 (1999) 576-582
76. Kooijman R., Buul-Offers S.v., Scholtens E.J., Schuurman H.J., Brande J.V.d., and Zegers Z.J.M. Cell development in insulin-like growth factor II transgenic mice. J Immunol 154 (1995) 5736-5745
77. Kooijman R., Buul-Offers S.v., Scholtens L.E., Reijnen-Gresnight R.G., and Zegers B.J.M. B cell development in pituitary deficient insulin-like growth factor-II transgenic dwarf mice. J Endocrinol 155 (1997) 165-170
78. Berczi I. Hormonal interactions between the pituitary and immune system. In: Grossman C.J. (Ed). Bilateral Communication Between the Endocrine and Immune Systems (1994), Springer, Berlin 96-144
79. Besedovsky H.O., del Rey A., Klusman I., Furukawa H., Monge Arditi G., and Kabiersch A. Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J Steroid Biochem Mol Biol 40 (1991) 613-618
80. Tsagarakis S., and Grossman A. Corticotropin-releasing hormone: interactions with the immune system. Neuroimmunomodulation 1 (1994) 329-334
81. Karalis K., Sano H., and Redwine J. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254 (1991) 421-423
82. Turnbull A.V., Smith G.W., Lee S., Vale W.W., Lee K.F., and Rivier C. CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology 140 (1999) 1013-1017
83. Harbuz M.S., Conde G.L., Marti O., Lightman S.L., and Jessop D.S. The hypothalamic-pituitaryadrenal axis in autoimmunity. Ann N Y Acad Sci 823 (1997) 214-224
84. Boehme S.A., Gaur A., Crowe P.D., Liu X.J., Taniraz S., Wong T., Pahuja A., Ling N., Vale W., De Souza E.B., and Conton P. Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy. Cell Immunol 176 (1997) 103-112
85. Menzies R., Phelps C., Wiranowska M., Oliver J., Chen L., Horvath E., and Hall N. The effect of interferon-alph on the pituitary-adrenal axis. J Interferon Cytokine Res 16 (1996) 619-629
86. Raber J., Koob G.F., and Bloorn F.E. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response. Neurochem. Int. 30 (1977) 455-463
87. Smith E.M., Hughes T.K., Cadet P., and Stefano G.B. Corticotropin-releasing factor-induced immunosuppression in human and invertebrate immunocytes. Cell Mol Neurobiol 12 (1992) 473-481
88. Kim D.S., and Melme S. Stimulatory effect of leukemia inhibitory factor on ACTH secretion of dipersed rat pituitary cells. Endocr Res 25 (1999) 11
89. Kim D.S., Choi H.S., Park Y.S., and Kim T.W. Effect of oncostatin M on hormone release of rat pituitary cells in primary culture. J Korean Med Sci 15 (2000) 323-326
90. Zylinska K., Mucha S., Komorowski J., Korycka A., Pisarek H., Robak T., and Stepien H. Influence of granulocyte-macrophage colony stimulating factor on pituitary-adrenal axis (PAA) in rats in vivo. Pituitary 2 (1999) 211-692
91. Bethin K.E., Vogt S.K., and Muglia I.J. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 97 (2000) 9317-9322
92. Barna I., Bertok L., Koenig J.I., and Makara G.B. Radiodetoxified Lipopolysaccharide Fails to Activate the Hypophyscal-Pituitary-Adrenal Axis in the Rat. Neuroimmunomodulation 8 (2000) 128-131
93. Jessop D.S., Douthwaite J.A., Conde G.L., Lightman S.L., Dayan C.M., and Harbuz M.S. Effects of Acute Stress of Centrally Injected Interleukin-Ibeta on Neuropeptide Expression in the Immune System. Stress 2 (1997) 133-144
94. Schafer M., and Mousa S.A. Stein, Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol 323 (1997) 1-10
95. Kagecyama K., Bradbury M.J., Zhao L., Blount A.L., and Vale W.W. Urocortin messenger ribonucleic acid: tissue distribution in the rat and regulation in thymus by lipopolysaccharide and glucocorticoids. Endocrinology 140 (1999) 5651-5658
96. Okamoto S., Ishikawa I., Kimura K., and Saito M. Potent suppressive effects of urocortin on splenic lymphocyte activity in rats. Neuroreport 9 (1998) 4035-4039
97. Ichinose M., Sawada M., and M{high symbol}no T. Suppression of phagocytosis by adrenocorticotropic hormone in murine peritoneal macrophages. Immunol Lett 42 (1994) 161-165
98. Zimmer J.Z., and Lipton J.M. Central and peripheral injections of ACTH (1-24) reduce fever in adrenalectomized rabbits. Peptides 2 (1981) 413-417
99. Conti B., Sugama S., Kim Y., Tinti C., Kim H., Baker H., Volpe B., Attardi B., and Joh T. Modulation of IL-18 production in the adrenal cortex following acute ACTH or chronic corticosterone treatment. Neuroimmunomodulation 8 (2000) 1-7
100. Gaveriaux C., Peluso J., Simonin F., Laforet J., and Kieffer B. Identification of kappa and deltaopioid receptor transcripts in immune cells. FEBS Lett 369 (1995) 272-276
101. Chuang T.K., Killam K.R., Chuange L.E., Kung H.F., Sheng W.S., Chao C.C., Yu L., and Chuange R.Y. Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Comm 216 (1995) 922-930
102. Sedqi M., Roy S., Ramakrishnan S., Elde R., and Loh H.H. Complementary DNA cloning of a mu-opioid receptor from rat peritoneal macrophages. Biochem Biophys Res Commun 209 (1995) 563-574
103. Wiek M.J., Minnerath S.R., Roy S., Ramakrishnan S., and Loh H.H. Complementary DNA cloning of a mu-opioid receptor from rat peritoneal macrophages. Biochem Biophys Res Commun 209 (1995) 563-574
104. Wick M.J., Minnerath S.R., Roy S., Ramakrishnan S., and Loh H.H. Differential expression of opioid receptor genes in human lymphoid cell lines and peripheral blood lymphocytes. J Neuroimmunol 64 (1996) 29-36
105. Sharp B.M., Roy S., and Bidlack J.M. Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol 83 (1998) 45-56
106. Ruzicka B.B., and Akil H. Differential cellular regulation of pro-opiomelanocortin by interleukin-1β and corticotropin-releasing hormone. Neuroendocrinology 61 (1995) 136-151
107. Sacerdote P., Brini A.T., Locatelli L., Radulovie J., and Panerai A.E. Tumor necrosis factor alpha differentially regulates beta-endorphin concentrations and proopiomelanocortin RNA in the anterior and neurointermediate pituitary in vivo. Neuroimmunomodulation 1 (1994) 357
108. Panerai A.E., Radulovic J., Monastra G., Manfredi B., Locatelli L., and Sacerdote P. Betaendorphin concentrations in brain areas and peritoneal macrophages in rats susceptible and resistant to experimental allergic encephalomyclitis a possible relationship between tumor necrosis factor aipha and opioids in the disease. J Neuroimmunol 51 (1994) 169-175
109. Stein C., Schafer M., and Hassan A. Peripheral opioid receptors. Ann Med 27 (1995) 219-221
110. Plotnikoff N.P., Faith R.E., Murgo A.J., and Good R.A. Enkephalins and Endorphins: Stress and the Immune System (1986), Plenum Press, New York
111. Gilmore W., and Weiner L.P. Beta-Endorphin enhances interleakin-2 (IL-2) production in murine lymphocytes. J Neuroimmunol 18 (1988) 125-138
112. Stefano G.B. Role of opioid neuropeptides in immunoregulation. Prog Neurobiol 33 (1989) 149-159
113. Weber R.J., and Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science 245 (1989) 188-190
114. Apte R.N., Durun S.K., and Oppenheim J.J. Opioids modulate interleukin-1 production and secretion by hone-marrow macrophages. Immunol Lett 24 (1990) 141-148
115. Millar D.B., Hough C.J., Mazorow D.L., and Gootenberg J.E. Beta-endorphin's modulation of lymphocyte proliferation is dose, donor and time dependent. Brain Behav Immun. 4 (1990) 232-242
116. Chiappelli F., Nguyen L., Bullington R., and Fahey J.L. Beta-Endorphin blunts phosphatidylinosoitol formation during in vitro activation of isolated human lymphocytes: Preliminary report. Brain Behav Immun 6 (1992) 1-10
117. Bergh van den P., Dobber R., and Ramlal S. Role of opioid peptides in the regulation of cytokine production by murine CD4-T cells. Cell Immunol 154 (1994) 109-122
118. Hiddinga H.J., Isaak D.D., and Lewis R.V. Enkephalin-containing peptides processed from proenkephalin significantly enhance the antibody-forming cell responses to antigens. J Immunol 152 (1994) 3748-3759
119. Mazorow D.L., Simpkins C.O., and Millar D.B. Beta-endorphin modulates calcium channel activity in human neutrophils. J Neuroimmunol 50 (1994) 77-83
120. Machelska H., Cabot P.J., Mousa S.A., Zhang Q., and Stein C. Pain control in inflammation governed by selectins. Nat Med 4 (1998) 1425-1428
121. Aymerich M.S., Bengoechea-Alonso M.T., Lopez-Zabalza M.J., Santiago E., and Lopez-Moratalla. Inductible pitric oxide synthase (iNOS) expression in human monocytes triggered by betaendorphin through an increase in cAMF. Biochem Biophys Res Commun 245 (1988) 717-721
122. Pasnik J., Tchorzewski H., Baj Z., Luciak M., and Tchorzewski M. Priming effect of metenkephalin and beta-endorphin on chemiluminescence, chemotaxis and CD11b molecule expression on human neutrophils in vitro. Immunol Lett 67 (1999) 77-83
123. Jessop D.S., Major G.N., Coventry T.L., Kaye S.J., Fulford A.J., Harbuz M.S., and De Bree F.M. Novel opioid peptides endomorphin-l and endomorphin-2 are present in mammalian immune tissues. J. Neuroimmunol 106 (2000) 53-59
124. Azuma Y., Want P., Shinohara M., and Obura K. Immunomodulation of the neutrophil respiratory burst by endomorphins 1 and 2. Immunol Lett 75 (2000) 55-59
125. Dimitrijevic M., Stanojevie S., Kovacevic-Jovanovic V., Miletic T., Vuji-Redzic V., and Radulovic J. Modulation of humoral immune responses in the rat by centrally applied Met-Enk and opioid receptor antagonists: functional interactions of brain OPL, OP2 and OP3 receptors. Immunopharmacology 49 (2000) 255-262
126. Catania A., and Lipton J.M. The neuropeptide alpha-melanocyte-stimulating hormone: a key component of neuroimmunomodulation. Neuroimmunomodulation 1 (1994) 93-99
127. Papadopoulos A.D., and Wardlaw S.L. Endogeous alpha-MSH modulates the hypothalamie pituitary-adrenal response to the cytokine interleukin-Ibeta. J Neuroendocrinol 11 (1999) 315-319
128. Brzoska T., Kalden D.H., Scholzen T., and Luger T.A. Molecular basis of the α-MSH/IL-1 antagonism. Ann NY Acad Sci 885 (1999) 230-238
129. Lipton J.M., and Catania A. Mechanisms of antiinflammatory action of the neuroimmunonodulatory peptide α-MSH. Ann NY Acad Sci 840 (1998) 373-380
130. Blalock J.E. Proopiomelanocortin and the immune-neuroendocrine connection. Ann NY Acad Sci 885 (1999) 161-172
131. Luger T.A., Kalden D., Scholzen T.E., and Brzoska T. α-MSH as a mediator of tolerace induction. Pathobiology 67 (1999) 318-321
132. Luger T.A., Schwarz T., Kalden H., Scholzen T., Schwarz A., and Brzoska T. Role of epidermal cell-derived α-MSH in ultraviolet light mediated local immunosuppresion. Ann NY Acad Sci 885 (1999) 209-216
133. Jessop D.S., Jukes K.E., and Lightman S.L. Resease of alpha-melamocyte-stimulating hormone from rat splenocytes in vitro is dependent on protein synthesis. Immunol Lett 41 (1994) 191-194
134. Schauer E., Trautinger F., and Kock A. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest 93 (1994) 2258-2262
135. Taylor A.W., Strelein J.W., and Cousins S.W. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol 153 (1994) 1080-1086
136. Shoninski A., Wortsman J., Luger T., Paus R., and Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 80 (2000) 979-1020
137. Glyn-Ballinger J.R., Bernardini G.L., and Lipton J.M. Alpha-MSH injected into the septal region reduces fever in rabbits. Peptides 4 (1983) 199
138. Murphy M.T., Richards D.B., and Lipton J.M. Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone. Science 221 (1983) 192-193
139. Cannon J.G., Tatro J.B., Reichin S., and Dinarello C.A. Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin I. J Immunol 337 (1986) 2232-2236
140. Dardenne M., Itoh T., and Homo-Delarche F. Presence of glucocorticoid receptors in cultured thymic epithelial cells. Cell Immunol 100 (1986) 112-118
141. Robertson B., Dostal K., and Daynes R.A. Neuropeptide regulation of inflammatory and immunologic responses: The capacity of α-melanocyte-stimulating hormone to inhibit tumor necrosis factor and IL-I-inducible biologie responses. J Immunol 140 (1988) 4300-4307
142. Sundar S.K., Becker K.J., and Cierpial M.A. Intracerebro-ventricular infusion of interleukin I rapidly decreases peripheral cellular immune responses. Proc Natl Acad Sci USA (1989) 6398-6402
143. Goelst K., Mitchell D., and Laburn H. Effects of α-melanocyte stimulating hormone on fever caused by endotoxin in rabbits. J Physiol 441 (1991) 469-476
144. Taylor A.W., Streilein J.W., and Cousins S.W. Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Neuroimmunomodulation 1 (1994) 188-194
145. Bhardwaj R.S., Schwarz A., Becher E., Mahnke K., Aragane Y., Schwarz T., and Luger T.A. Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. J Immunol 156 (1996) 2517-2521
146. Luger T.A., Scholzen T., Brzoska T., Becher E., Stominski A., and Paus R. Cutaneous immunomodulation and coordination of skin stress respones by α-MSH. Ann NY Acad Sci 840 (1998) 381-394
147. Meilado M., Fermandez-Agullo T., Rodriguez-Frade J.M., San Frutos M.G., de la Pena P., Martinez-A C., and Montoya E. Expression analysis of the thyrotropin-felasing hormone receptor (TRHR) in the immune system using agonist anti-TRHR monoclonal antibodies. FEBS Lett 451 (1999) 308-314
148. Luger T.A., Scholzen T., Brzoska T., Becher E., Slominski A., and Paus R. Cutaneous immunomodulation and coordination of skin stress responses by α-MSH. Ann NY Acad Sci 840 (1998) 381-394
149. Raiden S., Polack E., Nahmod V., Labeur M., Holsboer F., and Larzt E. TRH receptor on immune cells: in vitro and in vivo stimulation of human lymphocyte and rat splenocyte DNA synthesis by TRH. J Clin Immunol 15 (1995) 242-249
150. Wang J., and Klein J.R. Thymus-neuroendocrine interactions in extrathymic T cell development. Science 265 (1994) 1860-1862
151. Komorowski J., Zylinska K., Pawlikowski M., and Stepien H. Stimulatory effect of thyrotropin (TSH) on interleukin-2 (IL-2) release from human peripheral blood lymphocytes. A dose-response study in vitro. Hormones Metab Res 25 (1993) 598-599
152. Grasso G., Massai L., De Leo V., and Muscettola M. The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro. Life Sci 62 (1998) 2005-2014
153. Van den Berghe G., de Zegher F., Vlasselaers D., Schetz M., Verwaest C., Ferdinande P., and Lauwers P. Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Crit Care Med 24 (1996) 590-595
154. Bagriacik E.U., and Klein J.R. The thyrotropin (thyroid-stimulating hormone) receptor is expressed on murine dendritic cells and on a subset of CD45RB high lymph node T cells: functional role for thyroid-stimulating hormone during immune activation. J Immunol 164 (2000) 6158-6165
155. Harbour D.V., Leon S., Kearing C., and Hughes K. Thyrotropin modulates B-cell function through specific bioactive receptors. Prog Neuroendocrinimmunol 3 (1990) 266-276
156. Coutelier J.P., Kehrl J., and Bellur S.S. Binding and functional effects of thyroid stimulating hormone on human immune cells. J Clin Immunol 10 (1990) 204-210
157. Provinciali M., Di Stefano G., and Fabris N. Improvement in the proliferative capacity and natural killer cell activity of murine spleen lymphocytes by thyrotropin. Int J Immunopharmacol 14 (1992) 865-870
158. Todd I., Pujol-Borrell R., Hammond L.J., McNally J.M., Feldman M., and Bottazzo G.F. Enhancement of thyrocyte HLA class II expression by thyroid stimulating hormone. Clin Exp Immunol 69 (1987) 524-531
159. Whetsell M., Bagriacik E.U., Seetharamaiah G.S., Prabhakar B.S., and Klein J.R. Neuroendocrine-induced synthesis of bone marrow-derived cytokines with inflammatory immunomodulating properties. Cell Immunol 192 (1999) 159-166
160. Peele M.E., Carr F.E., Baker Jr. J.R., Wartofsky I., and Burman K.D. TSH beta subunit gene expression in human lymphocyte. Am J Med Sci 305 (1993) 1-7
161. Fabris N., Mocchegiani E., and Provinciali M. Pituitary-thyroid axis and immune system: a reciprocal neuroendocrine-immune interaction. Horm Res 43 (1995) 29-38
162. Haddad E.E., and Mashaly M.M. In vivo effects of TRH, T3 and cGH on antibody production and lymphocytes-T and lymphocytes-B proliferation in immature male chickens. Immunol Invest 20 (1991) 557-568
163. Stein-Streilein J., Zakarija M., Papic M., and McKenzic J.M. Hyperthyroxinemic mice have reduced natural killer cell activity: Evidence for a defective trigger mechanism. J Immunol 139 (1987) 2502-2507
164. Turaihi K., Khan F.A., Baron D.N., and Dandona P. Effect of short term triiodothyronine administration on human leukocyte Fb (K) influx and Na efflux. J Clin Endocrinol Metab 65 (1987) 1031-1034
165. Schoenfeld P.S., Myers J.W., Myers L., and LaRocque J.C. Suppression of cell-mediated immunity in hypothyroidism. South Med J 88 (1995) 347-349
166. Ohashi H., and Itoh M. Effects of thyroid hormones on the lymphocyte phenotypes in rats: changes in lymphocyte subsets related to thyroid function. Endocr Regul 18 (1994) 117-123
167. Cole N.A., Allowvan R.H., Rodrigues S.L., and Purdy C.W. Influence of triiodothyronine injections on calf immune response to an infectious bovine rhinotracheitis virus challenge and nitrogen balance of lambs. J Amin Sci 72 (1994) 1263-1273
168. Ingram K.G., Crouch D.A., Douez d., Croy B.A., and Woodward B. Effects
169. Wang J., and Klein J.R. Hormone regulation of murine T cells: potent tissue-specific immunosuppressive effects of thyroxine targeted to gut T cells. Int Immunol 8 (1996) 231-235
170. Mariani E., Ravaglia G., Forti P., Menegbetti A., Tarozzi A., Maioli F., Boschi F., Pratelli L., Pizzoferrato A., Piras F., and Facchini A. Vitamin D, thyroid hormones and muscle mass influence natural killer (NK) innate immunity in healthy nonagenarians and centenarians. Clin Exp Immunol 117 (1999) 206
171. Simons P.J., Delemarre F.G., and Drexhage H.A. Antigen-presenting dendritic cells as regulators of the growth of thyrocytes: a role of interleukin-1 beta and interleukin-6. Endocrinology 139 (1998) 3148-3156
172. Rasmussen A.K. Cytokine actions on the thyroid gland. Dan Med Bull 47 (2000) 94-114
173. Brtko J., Jurcovicova J., Schmutzler C., Rokyta R., Svik K., and Bobal'ova J. Adjuvant arthritis in the rat is associated with decreased binding of nuclear receptors to thyroid hormone responsive element in spleen extracts. Gen Physiol Biophys 17 (1998) 341-347
174. Dorshkind K., and Horseman N. The roles of prolactin, growth hormone, insulin-like growth factor-I and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocrine Rev 21 (2000) 292-312
175. Gee A.P., Boyle M.D.P., and Munger K.L. Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci USA 80 (1983) 7213-7218
176. Boyle M.D.P., Lawman M.J.P., Gee A.P., and Young M. Nerve growth factor: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol 135 (1985) 564-568
177. Bornstein S.R., Licinio J., Tauchnitz R., Engelmann L., Negrao A.B., Gold P., and Chrousos G.P. Plasma leptin levels are increased in survivors of acute spesis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab 83 (1998) 280-283
178. Giovambattista A., Chisari A.N., Corro L., Gaillard R.C., and Spinedi E. Metabolic, neuroendocrine and immune functions in basal conditions and during the acute-phase response to endotoxic shock in undernourished rats. Neuroimmunomodulation 7 (2000) 92-98
179. Okamoto S., Irie Y., Ishikawa I., Kimura K., and Masayuki S. Central leptin suppresses splenic lymphocyte functions through activation of the corticotropin-releasing hormone-sympathetic nervous system. Brain Res 855 (2000) 192-197
180. Chautard T., Spinedi E., Voirol M., Pralong F.P., and Gaillard R.C. Role of glucocorticoids in the response of the hypothalamo-corticotrope, immune and adipose systems to repeated endotoxin administration. Neuroendocrinology 69 (1999) 360-369
181. Torpy D.J., Bornstein S.R., and Chrousos G.P. Leptin and interleukin-6 in sepsis. Horm Metab Res 30 (1998) 726-729
182. Faggioni R., Fantuzzi G., Gabay C., Moser A., Dinarello C.A., Feingold K.R., and Grunfeld C. Leptin deficiency enhances sensitivity to endotoxin-induced lethality. Am J Physiol 276 (1999) R136-R142
183. Takahashi N., Waelput W., and Guisez Y. Leptin is an endogenous protective protein against the toxicity exerted by tumor necrosis factor. J Exp Med 189 (1999) 207-212
184. Finck B.N., Kelley K.W., Dantzer R., and Johnson R.W. In vivo and in vitro evidence for the involvement of tumor necrosis factor-alpha in the induction of leptin by lipopolysaccharide. Endocrinology 139 (1998) 2278-2283
185. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., Klein A.S., Bulkley G.B., Bao C., Noble P.W., Lane M.D., and Diehl A.M. Leptin regulates proinflammatory immune responses. FASEB J 12 (1998) 57-65
186. Fantuzzi G., and Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68 (2000) 437-446
187. Malkinson T.J., Bridges T.E., Lederis K., and Vaele W.L. Perfusion of the septum of the rabbit with vasopressin antiserum enhances endotoxin fever. Peptides 8 (1987) 385-389
188. Torres B.A., and Johnson H.W. Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-γ production: evidence for a novel AVP receptor on mouse lymphocytes. J Immunol 140 (1988) 2179-2183
189. Lee H.R., Ho W.Z., and Douglas S.D. Substance P augments tumor necrosis factor release in human monocyte-derived macrophages. Clin Diagn Lab Immunol 1 (1994) 419
190. Nair M.P.N., and Schwartz S.A. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J Immunol 132 (1984) 2876-2882
191. Chancellor-Freeland C., Zhu G.F., Kage R., Beller D.I., Leeman S.E., and Black P.H. Substance P and stress-induced changes in macrophages. Ann NY Acad Sci 771 (1995) 472-484
192. Payan D.G., McGillis J.P., Renold F.K., Mitsuhashi M., and Goetzl E.J. The immunomodulating properties of neuropeptides. In: Berczi I., and Kovacs K. (Eds). Hormones and Immunity (1987), MTP Press, Lancaster, England
193. Foreman J.C. Neuropeptides and the pathogesis of allergy. Allergy 42 (1987) 1-11
194. Shanahan F., Lee T.D.G., Bienenstock J., and Befus A.D. Mast cell heterogeneity: Effect of anti-allergic compounds on neuropeptide-induced histamine release. Int Arch Allergy Appl Immunol 80 (1986) 424-426
195. Jancso G., Obal Jr. F.a.-K.I., Katona M., and Husz S. The modulation of cutaneous inflammatory reactions by peptide-containing sensory nerves. Int J Tissue React 7 (1985) 449-457
196. 2- concentration and inositol phosphate formation. J Immunol 141 (1988) 2118-2124
197. Lotz M., Carson D.A., and Vaughan J.H. Substance P activation of rheumatoid synoviocytes: Neural pathway in pathogenesis of arthritis. Science 235 (1987) 893-895
198. Hartung H.P., Heininger K., Schafer B., and Toyka K.V. Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism. Fed Am Soc Exp Bio J 2 (1988) 48-51
199. Rameshar P., Ganea D., and Gascon P. Induction of IL-3 and granulocyte-macrophage colony-stimulating factor by substance P in bone marrow cells is partially mediated through the release of IL-1 and IL-6. J Immunol 152 (1994) 4044-4054
200. Damonneville M., Monte D., Auriault C., and Capron A. The neuropeptide substance-P stimulates the effector functions of platelets. Clin Exp Immunol 81 (1990) 346-351
201. Nong Y.H., Titus R.G., Ribeiro J.M.C., and Remold H.G. Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 145 (1989) 45-49
202. Wang F., Millet I., Bottomly K., and Vignery A. Calcitonin gene-related peptide inhibits interleukin 2 production by murine T lymphocytes. J Biol Chem 267 (1992) 21052-21057
203. Wang J., and Klein J.R. Thymus-neuroendocrine interactions in extrathymic T cell development. Science 265 (1994) 1860-1862
204. Foris G., Gyimesi E., and Komaromi I. The mechanism of antibody-dependent cellular cytotoxicity stimulation by somatostatin in rat peritoneal macrophages. Cell Immunol 90 (1985) 217-225
205. Muscettola M., and Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiology 180 (1990) 419-430
206. Church M.K., El-Lati S., and Caulfied J.P. Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 94 (1991) 310-318
207. Fuente de la M., Delgado M., de Rio M., Garrido E., Leceta J., Hernanz A., and Gomariz R.P. Vasoactive intestinal peptide modulation of adherence and mobility in rat peritoncal lymphocytes and macrophages. Peptides 15 (1994) 1157-1163
208. Ichinose M., Asai M., Imai K., and Sawada M. Enhancement of phagocytosis in mouse macrophages by pituitary adenylate cyclase activating polypeptide (PACAP) and related peptides. Immunopharmacology 30 (1995) 217-224
209. Leceta J., Martinez M.C., Delgado M., Garrido E., and Gomariz R.P. Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat. Peptides 15 (1994) 791-797
210. Delgado M., and Ganea D. Inhibition of IFN-gamma-induced janus kinase-I-STATl activation in macrophages by vasoactive intestinal, peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165 (2000) 3051-3057
211. Sun W., Tadmori I., Yang L., Delgado M., and Ganea D. Vasoactive intestinal peptide (VIP) inhibits TGF-betal production in murine macrophages. J Neuroimmunol 107 (2000) 88-99
212. Xin Z., and Sriram S. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J Neuroimmunol 89 (1998) 206-212
213. Kawamura N., Tamura H., Obana S., Wenner M., Ishikawa T., Nakata A., and Yamamoto H. Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation 5 (1998) 9-15
214. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganca D., and Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol 63 (1998) 591-601
215. Tang H., Sun L., Xin Z., and Ganea D. Down-regulation of cytokine expression in murine lymphocytes by PACAP and VIP. Ann N Y Acad Sci 805 (1996) 768-778
216. Berczi I. Neuroimmune Biology: An introduction. In: Berczi I., and Gorczynski R. (Eds). Neuroimmune Biology Volume 1: New foundation of Biology I (2001), Elsevier 3-45
217. Homo-Delarche F., and Duval D. Glucocorticoid receptors in lymphoid tissue. In: Berczi I., and Kovacs K. (Eds). Hormones and Immunity (1987), MTP Press, Lancaster, England 1-19
218. Miller A.H., Spencer R.L., Husain A., Rhee R., McEwen B.S., and Stein M. Differential expression of type I adrenal steroid receptors in immune tissues is associated with tissue-specific regulation of type II receptors by aldosterone. Endocrinology 133 (1993) 2133
219. Karin M., Ynag-Yen H.-F., Chambard J.-C., Deng T., and Saateioglu F. Vorious modes of gene regulation by nuclear receptors for steroid and thyroid hormones. Eur J Clin Pharmacol 45 (1993) S9-S15
220. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
221. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270 (1995) 286-290
222. Adcock I.M., Brown C.R., Gelder G.M., Shirasaki H., Peters M.J., and Barnes P.J. Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 268 (1995) C331-C338
223. Watson C.S., and Gametchu B. Membrane estrogen and glucocorticoid receptors-implications for hormonal control of immune function and autoimmunity. Int Immunopharmacol 1 (2001) 1049-1063
224. Angeli A., Masera R.G., Sartori M.L., Forturati N., Racca S., Dovio A., Staurenghi A., and Frairia R. Modulation by cytokines of glucocorticoid action. Ann NY Acad Sci 876 (1999) 210-220
225. Ahluwalia A., Newbold P., Brain S.D., and Flower R.J. Topical glucocorticods inhibit neurogenic inflammation: involvement of lipocortin 1. Eur J Pharmacol 283 (1995) 193-198
226. Taylor A.D., Loxley H.D., Flower R.J., and Buckingham J.C. Immunoneutralization of lipocortin 1 reverses the acute inhibitory effects of dexamethasone on the hypothalamo-pituitary-adrenocortical responses to cytokines in the rat in vitro and in vivo. Neuroendocrinology 62 (1995) 19-31
227. Barnes P.J., and Adcock I.M. Steroid resistance in asthma. QJ Med 88 (1995) 455-468
228. Harrlich P. Cross-talk between glucocorticoid receptor and AP-I. Oncogene 20 (2001) 2465-2475
229. Vacchio M.S., Papadopoulos, and Ashwell J.D. A eroid production in the thymus: implications for thymocyte selection. J Exp Med 179 (1994) 1835-1846
230. King L.B., Vacchio M.S., Dixon K., Hunziker R., Margulies D.H., and Ashwell J.D. A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. Immunity 3 (1995) 647-656
231. Vacchio M.S., Lee J.Y., and Ashwell J.D. Thymus-derived glucocorticoids set the thresholds for thymocyte selection by inhibition TCR-mediated thymocyte activation. J Immunol 163 (1999) 1327
232. Thompson E.B. Apoptosis and steroids. Mol Endocrinol 8 (1994) 665-673
233. Homo-Delarche F., Duval D., and Papiernik M. Prostaglandin production by phagocytic cells of the mouse thymic reticulum in culture and its modulation by indomethacin and corticosteroids. J Immunol 135 (1985) 506-512
234. Arzt E., Kovalovsky D., Igaz L.M., Costas M., Plazas P., Refojo D., Paez-Pereda M., Reul J.M., Stalla G., and Holsboer F. Functional cross-talk among cytokines, T-cell receptor, and glucocorticoid receptor transcriptional activity and action. Ann N Y Acad Sci 917 (2000) 672-677
235. Chao T.C., Van-Alten P.J., and Walter R.J. Steroid and sex hormones and macrophage function modulation of reactive oxygen intermediates and nitrite release. Amer J Reprod Immunol 32 (1994) 43-52
236. Munck A., Naray-Fejes-Toth A., and Guyre P.M. Mechanisms of glucocorticoid actions on the immune system. In: Berczi I., and Kovack K. (Eds). Hormones and Immunity (1987), MTP Press, Lancaster, England
237. Sauer J., Castren M., Hopfner U., Holsboer F., Stalla G.K., and Arzt E. Inhibition of lipopolysaccharide-induced monocyte interleukin-1 receptor antagonist synthesis by cortisol: involvement of the mineralocorticoid receptor. J Clin Endocrinol Metab 81 (1996) 73-79
238. Gerrard T.L., Cupps T.R., Jurgensen C.H., and Fauci A.S. Increased expression of HLA-DR antigens in hydrocortisone-treated monocytes. Cell Immunol 84 (1984) 311-316
239. Strickland R.W., Wahl L.M., and Finbloom D.S. Corticosteroids enhance the binding of recombinant interferon-gamma to cultured human monocytes. J Immunol 137 (1986) 1577-1580
240. Girard M.T., Jhaltadottir S., Fejes-Toth A.N., and Guyre P.M. Glucocorticoids enhance the γ-interferon augmentation of human monocyte immunoglobulin G Fe receptor expression. J Immunol 138 (1987) 3235-3241
241. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., Cerami A., and Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377 (1995) 68
242. Franchimont D., Galon J., Gadina M., Visconti R., Zhou Y., Aringer M., Frucht D.M., Chrousos G.P., and O'Shea J.J. Inhibition of Thl immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Sta4 phosphorylation in T lymphocytes. J Immunol 164 (2000) 1768-1774
243. 2 are additive inhibitors of human natural killer cell activity. Immunopharmacology 11 (1986) 119-128
244. Schleimer R.P. An overview of glucocorticoid anti-inflamatory actions. Eur J Clin Pharmacol 45 (1993) S3-S7
245. Sternberg E.M. Neuroendocrine factors in susceptibility to inflammatory disease: focus on the hypothalamic-pituitary-adrenal axis. Horm Res 43 (1995) 159-161
246. Karalis K., Sano H., and Redwine J. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science (1991) 421-423
247. Molijin G.J., Spek J.J., vanUffelen J.C.J., de Jong F.H., Brinkmann A.O., Bruining H.A., Lamberts S.W.J., and Koper J.W. Differential adaption of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 80 (1995) 1799-1803
248. Lavker R.M., and Schechter N.M. Cutaneous mast cell depletion results from topical corticosteroid usage. J Immunol 135 (1985) 2368-2373
249. Bergstrand H., Bjornsson A., Lundquist B., Nilsson A., and Brattsand R. Inhibitory effect of glucocorticosteroids on anti-IgE-induced histamine release from human basophilic leukocytes: Evidence for a dual mechanism of action. Allergy 39 (1983) 217-230
250. Bakker J.M., Kavelaars A., Kamphuis P.I., Cobelens P.M., van Vugt H.H., van Bel F., and Heijnen C.J. Neonatal dexamethasone treatment increases susceptibility to experimental autoimmune disease in adult rats. J Immunol 165 (2000) 5932-5937
251. Ruzek M.C., Pearce B.D., Miller A.H., and Biron C.A. Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. J Immunol 162 (1999) 3527-3533
252. Miller A.H., Spencer R.L., Hassett J., Kim C., Rhee R., Ciurea D., Dhabhar F., McEwen B., and Stein M. Effects of selective type I and II adrenal steroid agonists on immune cell distribution. Endocrinology 135 (1994) 1934-1944
253. Cannon J.G. Adaptive interactions between cytokines and the hypothalamic pituitarygonadal axis. Ann N Y Acad Sci 856 (1998) 234-242
254. Kalra P.S., Edwards T.G., Xu B., Jain M., and Kalra S.P. The anti-gonadotropic effects of cytokines: the role of neuropeptides. Domest Anim Endocrinol 15 (1998) 321-332
255. In: Grossman C.G. (Ed). Bilateral Communication between the Endocrine and Immune Systems (1994), Springer-Verlag, New York
256. Stimson W.H. Sex steroids, steroid receptors and immunity. In: Berczi I., and Kovacs K. (Eds). Hormones and Immunity (1987), MTP Press, Lancaster, England 43-53
257. Myers J.M., Heim M.C., Hirsch K.S., Queener S.F., and Peterson B.H. Translocatable estrogen receptors in rat splenocytes. Life Sci 39 (1986) 313-320
258. Kovacs W.J., and Olsen N.J. Androgen receptors in human thymocytes. J Immunol 139 (1987) 490-493
259. Baral E., Nagy E., and Berczi I. The effect of tamoxifen on the immune response. In: Kellen J.A. (Ed). Tamoxifen beyond the antiestrogen (1996), Birkhauser, Boston 137-178
260. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., and Webb P. Estrogen receptor pathway to AP-1. J Steroid Biochem Mol Biol 74 (2000) 311-317
261. Kato S.S. Estrogen receptor-mediated cross-talk with growth factor signaling pathways. Breast Cancer 8 (2001) 3-9
262. Ray P., Ghosh S.K., Zhang D.H., and Ray A. Repression of interleukin-6 gene expression by 17 beta-estradiol; inhibition of the DNA-binding activity of the transcription factors NF-IL 6 and NF-kappa B by the estrogen receptor. FEBS Lett 409 (1997) 79-85
263. DeMarzo A.M., Beck C.A., Onate S.A., and Edwards D.P. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-k-Da heat shock protein. Proc Natl Acad. Sci USA 88 (1991) 72-76
264. Mohamed M.K., Tung L., Takimoto G.S., and Horwitz K.B. The leucine zippers of c-fos and c-jun for progesteronc receptor dimerization: A-dominance in the A/B heterodimer. J Steroid Biochem Mol Biol 51 (1994) 241-250
265. Conneely O.M. Perspective: female steroid hormone action. Endocrinology 142 (2001) 2194-2199
266. Nelson J.L., and Steinberg A.D. Sex steroids, autoimmunity and autoimmune disease. In: Berczi I., and Kovacs K. (Eds). Hormones and Immunity (1987), MTP Press, Lancaster, England 93-119
267. Bereczi I., Chalmers I.M., Nagy E., and Warrington R.J. The immune effects of neuropeptides. Bailliere Clin Rheumatol 10 (1996) 227-257
268. Robert R., and Spitzer J.A. Effects of female hormones (17beta-estradiol and progesterone) on nitric oxide production by alveolar macrophages in rats. Nitric Oxide 1 (1997) 453-462
269. Salem M.L., Hossain M.S., and Nomoto K. Mediation of the immunomodulatory effect of beta-estradiol on inflammatory responses by inhibition of recruitment and activation of inflammatory cells and their gene expression of TNF-alpha and IFN-gamma. Int Arch Allergy Immunol 121 (2000) 235-245
270. Nilsson N., and Carlsten H. Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cell Immunol 158 (1994) 131-139
271. Keller E.T., Zhang J., Yao Z., and Qi Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovaricctomized rhesus monkey (Macaca mulata) model of menopause. J Reprod Immunol 50 (2001) 41-55
272. Gilmore W., Weiner L.P., and Correale J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J. Immunol 158 (1997) 446-451
273. Orvieto R., Ben-Rafael Z., Abir R., Bar-Hava I., Fisch B., and Molad Y. Controlled ovarian hyperstimulation: a state of neutrophil activation. Am J Reprod Immunol 42 (1999) 288-291
274. Berczi I., Chow D.A., Baral E., and Nagy E. Neuroimmunoregulation and cancer. Int J Oncol 13 (1998) 1049-1051
275. Nagy E., Baral E., and Berczi I. Immune System. In: Oettel M. (Ed). Handbook of Experimental Pharmacology: Estrogens and anti-estrogens. Section IV. Physiology and Pathophysiology of Estrogens. Jena, Germany 135/I (1999), Springer-Verlag 343-351
276. Nagy E., Berczi I., and Baral E. Combination immunotherapy of cancer. In: Berczi I., and Gorczynski R. (Eds). Neuroimmuine Biology: New Foundations of Biology (2001), Elsevier, Amsterdam: 417-432
277. Nagy E., and Berczi I. Immunomodulation by tamoxifen and pergolide. Immunopharmacology 12 (1986) 145-153
278. Baral E., Nagy E., and Berczi I. Modulation of natural killer cell mediated cytotoxicity by tamoxifen and estradiol. Cancer 75 (1995) 591-599
279. Baral E., Nagy E., and Berczi I. Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen. Int J Cancer 66 (1996) 214-218
280. Baral E., Nagy E., Kangas L., and Berczi L. Anti-estrogens enhance the therapeutic effect of lymphokine activated killer cells on the P815 murine mastocytoma. Int J Cancer 67 (1996) 580-585
281. Baral E., Nagy E., Kangas L., and Berczi I. Immunotherapy of the SL 2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene. Anticancer Res 17 (1997) 77-84
282. Baral E., Nagy E., Kangas L., and Berczi I. Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens. Anticancer Res 17 (1997) 3647-3652
283. Baral E., Nagy E., Kangas L., and Berczi I. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens. Anticancer Res 17 (1997) 3653-3658
284. Haeryfar S.M.M., Nagy E., Baral E., Krepart G.E., Lotocki R.J., and Berczi I. Antiestrogens affect both pathways of killer cell-mediated oncolysis. Anticancer Res 20 (2000) 1849-1853
285. Nagy E., Baral E., Kangas L., and Berezi I. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes. Anticancer Res 17 (1997) 1083-1088
286. Baral E., Nagy E., Krepart G.E., Lotocki R.J., Unruh H.W., and Berczi I. Antiestrogen sensitize human ovarian and lung carcinomas for lysis by autologous killer cells. Anticancer Res 20 (2000) 2027-2031
287. Zhou Z., Shackleton C.H., Pahwa S., White P.C., and Speiser P.W. Prominent sex steroid metabolism in human lymphocytes. Mol Cell Endocrinol 138 (1998) 61-69
288. Ravache E.S., and Steiberg A.D. Sex hormones in autoimmunity. In: Berczi I. (Ed). Pituitary Function and Immunity (1986), CRC Press, Boca Raton, CA 283-301
289. Ahmed S.A., Talal N., and Christados P. Genetic regulation of testosterone-induced immune suppression. Cell Immunol 104 (1987) 91-98
290. Fried W., and Morley C. Effects of androgenic steroids on erythropoiesis. Steroids 46 (1985) 799-826
291. Greenstein B.D., de Bridges E.F., and Fitzpatrick F.T. Aromatase inhibitors regenerate the thymus in aging male rats. Int J Immunopharmacol 14 (1992) 541-553
292. Araneo B.A., Dowell T., Diegel M., and Daynes R.A. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5 and γ-interferon, but not IL-2 by activated murine T cells. Blood 78 (1991) 688-699
293. Friedl R., Brunner M., Moeslinger T., and Spieckermann P.G. Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages. Life Sci 68 (2000) 417-429
294. Gomez F., Ruiz P., Lopez R., Rivera C., Romero S., and Bernal J.A. Effects of androgen treatment on expression of macrophage Fegamma receptors. Clin Diagn Lab Immunol 7 (2000) 682-686
295. Giltay E.J., Fonk J.C., von Blomberg B.M., Drexhage H.A., Schalkwijk C., and Gooren L.J. In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab 85 (2000) 1648-1657
296. Olsen N.J., Zhou P., Ong H., and Kovacs W.J. Testosterone induces expression of transforming growth factor-beta 1 in the murine thymus. J Steroid Biochem Mol Biol. 45 (1993) 327-332
297. Angele M.K., Knoferl M.W., Schwacha M.G., Ayala A., Cioffi W.G., Bland K.I., and Chaudry I.H. Sex steroids regulate pro- and anti-inflammatory cytokine release by macrophages after trauma-hemorrhage. Am J Physiol 277 1 Pt 1 (1999) C35-C42
298. Angele M.K., Schwacha M.G., Ayala A., and Chaudry I.H. Effect of gender and sex hormones on immune responses following shock. Shock 14 (2000) 81-90
299. Mortin R., and Courchay G. Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites which increase the immune response in mice. J Steroid Biochem Molec Biol 50 (1994) 91-100
300. McLachlan J.A., Serkin C.D., and Bakouche O. Dehydroepiandrosterone modulation of lipopoly saccharide-stimulated monocyte cytotoxicity. J Immunol 156 (1996) 328-335
301. Regelson W., Loria R., and Kalimi M. Dehydroepiandrosterone (DHLA)-the "mother steroid". I immunologic action. Ann NY Acad Sci 719 (1994) 553-563
302. Hall G.M., Perry L.A., and Spector T.D. Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. Ann Rheum Dis 52 (1993) 211-214
303. Casson P.R., Andersen R.N., Herrod H.G., Stentz F.B., Straughn A.B., Abraham G.F., and Buster J.E. Oral dehydroepiandrosterone in physiologic doses modulates, immune function in postmenopausal women. Am J Obstet Gynecol 169 (1993) 1563-1569
304. Kalo-Klein A., and Witkin S.S. Regulation of the immune response to Candida albicans by monocytes and progesterone. Am J Obstet Gynecol 164 (1991) 1351-1354
305. Nohmi T., Abe S., Dobashi K., Tansho S., and Yamaguchi H. Suppression of anti-Candida activity of murine neutrophils by progesterone in vitro: a possible mechanism in pregnant women's vulerability to vaginal candidiasis. Microbiol Immunol 39 (1995) 405-409
306. Chao T.C., Van Alten P.J., Greager J.A., and Walter R.J. Steroid sex hormones regulate the release of tumor necrosis factor by macrophages. Cell Immunol 160 (1995) 43-49
307. Li Z.G., Danis V.A., and Brooks P.M. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin Exp Rhematol 11 (1993) 157-162
308. Scarpellini F., Scarpellini L., Dino N., and Benvenuto P. Progesterone immunosupreessive levels and luteal steroid profiles in the cycles induced with clomiphene citrate. Clin Exp Obstet Gynecol 20 (1993) 182-188
309. Check J.H., Tarquini P., Gandy P., and Lauer C. A randomized study comparing the efficacy of reducing the spontaneous abortion rate following lymphocyte immunotherapy and progesterone treatment versus progesterone alone in primary habitual aborters. Gyncecol Obstet Invest 39 (1995) 257-261
310. Szekeres-Bartho J., Barakonyi A., Par G., Polgar B., Palkovics T., and Szereday L. Progesterone as an immunomodulatory molecule. Int Immunopharmacol 1 (2001) 1037-1048
311. McMurray R.W., Wilson J.G., Bigler L., Xiang L., and Lagoo A. Progesterone inhibits glucocorticoid-induced murine thymocyte apoptosis. Int J Immunopharmacol 22 (2000) 955-965
312. Fleming M.W., and Gamble H.R. Consequences of dose-dependent immunosuppression by progesterone on parasitic worm burdens in lambs. Am J Vet Res 54 (1993) 1299-1302
313. Parr M.B., Kepple L., McDermott M.R., Drew M.D., Bozzola J.J., and Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70 (1994) 369-380
314. Manolagas S.C., Yu X.-P., Girasole G., and Bellido T. Vitamin D and the hematolymphopoictic tissue: a 1994 update. Sem Nephrol 14 (1994) 129-143
315. Bouillon R., Garmyn M., Verstuyf A., Segaert S., Casteels K., and Mathieu C. Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analog. Euro J Endocrinol 133 (1995) 7-16
316. Jones G., Strugnell S.A., and DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol Rev 78 (1998) 1193-1231
317. Veldman C.M., Cantorna M.T., and DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 374 (2000) 334-338
318. Twers T.L., Staeva T.P., and Freedman L.P. A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Mol Cell Biol 19 (1999) 4191-4199
319. Cippitelli M., and Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 28 (1998) 3017-3030
320. Holick M.F. Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications. Bone 17 (1995) 107S-111S
321. Nowotny A. In search of active sites in endotoxins. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 1-55
322. Boivin A., Mesrobeanu J., and Mesrobeanu D. Technique pour la preparation des polysaccharides microbiens specifiques. CR Soc Biol 113 (1933) 490
323. Greisman S.E. Induction of endotoxin tolerance. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 149-178
324. Behling U.H. The radioprotective effect of bacterial endotoxin. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 127-148
325. Parant M. Effect of LPS on nonspecific resistance to bacterial infections. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 179-196
326. Johnson A.G. Adjuvant action of bacterial endotoxins on antibody formation. A historical perspective. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 249-253
327. Butler R.C. Enhancement of nonspecific resistance to tumor by endotoxin. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 497-512
328. Walker R.I. Possibilities for use of endotoxin in compromised subjects. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 197-212
329. Abdelnoor A.M. Effect of LPS on the clotting system. In: Nowotny A. (Ed). Beneficial Effects of Endotoxins (1983), Plenum Press, New York 75-90
330. Cornell R.P. Restriction of gut-derived endotoxin impairs DNA synthesis for liver regeneration. Am J Physiol. 249 5 Pt 2 (1985) R563-R569
331. Windle W.F., and Chambers W.W. Regeneration in spinal cord of cat and dog. J Comp Neurol. 93 (1950) 241-258
332. Williams J.L., and Dick G.F. Decreased dextrose tolerance in acute infectious disease. Arch Intern Med 50 (1932) 801
333. Fox M.J., Kuzma J.F., and Washam W.T. Transitory diabetic syndromes associated with meningococcic meningitis. Arch Intern Med 79 (1947) 614
334. Beisel W.R. Metabolic response to infection. Ann Rev Med. 26 (1975) 9-20
335. Berczi I. The influence of pituitary adrenal axis on the immune system. In: Berczi I. (Ed). Pituitary function and immunity (1986), CRC Press, Boca Raton FL 49-132
336. Berkenbosch F., van Oers J., del Rey A., Tilders F., and Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-J. Science 238 (1987) 524-526
337. Sapolsky R., Rivier C., Yamamoto G., Plotsky P., and Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-relasing factor. Science 238 (1987) 522-524
338. Uehara A., Gottschall P.E., Dahl R.R., and Arimura A. Interleukin-1 stimulates ACTH relcase, by an indircct action which requires endogenous corticotropin releasing factor. Endocrinology 121 (1987) 1580-1582
339. Bernton E.W., Beach J.E., Holaday J.W., Smallridge R.C., and Fein H.G. Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 238 (1987) 519-521
340. Nakamura H., Motoyoshi S., and Kadokawa T. Anti-inflammatory action of interleukin 1 through the pituitary-adrenal axis in rats. Eur J Pharmacol. 151 (1988) 67-73
341. Selye H. A syndrome produced by diverse nocuous agents. Nature 138 (1936) 32
342. Selye H. Thymus and the adrenals in response of the organism to injuries and intoxications. Br J Exp Pathol 17 (1936) 234-248
343. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 6 (1946) 117-230
344. Selye H. Stress and disease. Science 122 (1955) 625
345. Selye H. Effect of ACTH and cortisone upon an "anaphylactoid reaction". Can Med Assoc J 61 (1949) 553-556
346. Selye H. Morphological changes in the fowl following chronic overdosage with various steroids. J Morphol 73 (1943) 401-421
347. Berczi I. Neurohormonal host defence in endotoxin shock. Ann NY Acad Sci 840 (1998) 787-802
348. Berczi I. the stress concept and neuroimmunoregulation in modern biology. Ann NY Acad Sci 851 (1998) 3-12
349. Haeryfar S.M.M., and Berczi I. The thymus and the acute phase response. Cell Mol Biol 47 (2001) 145-156
350. Berczi I., Bertok L., and Chow D. Natural immunity and neuroimmune host defence. Ann NY Acad Sci 917 (2001) 248-257
351. Berczi I., and Szentivanyi A. The acute phase response. In: Berczi I., and Szentivanyi A. (Eds). Neuroimmune Biology, Volume 4: The Immune-Neuroendocrine Circuitry. History and Progress (2003), Elsevier, Amsterdam
352. Westphal O., Jann K., and Himmelspach K. Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins. Prog Allergy 33 (1983) 9-39
353. Ramachandra R.N., Berczi A., Sehon A.H., and Berczi I. Inhibition of lipid A. and lipopolysaccharide (LPS) induced cytokine secretion, B cell mitogenesis and lethal shock by lipid A specific murine monoclonal antibodies. J Infect Dis 167 (1993) 1151-1159
354. Berczi I. Neuroendocrine defence in endotoxin shock. (A review). Acta Microbiol Hung 40 (1993) 265-302
355. Raetz C.R.H., Ulevitch R.J., Wright S.D., Sibley C.H., Ding A., and Nathan C.F. Gram-negative endotoxin: An extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 5 (1991) 2652-2660
356. Tobias P.S., Mathison J., Mintz D., Lee J.D., Kravchenko V., Kato K., Pugin J., and Ulevitch R.J. Participation of lipopolysaccharide-binding protein in lipopolysaccharide-dependent macrophage activation. Am J Respir Cell Mol Biol 7 (1992) 239-245
357. Schumann R.R. Function of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: a short review. Res Immunol. 143 (1992) 11-15
358. Mathison J.C., Tobias P.S., Wolfson E., and Ulevitch R.J. Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. J Immunol 149 (1992) 200-206
359. Haziot A., Chen S., Ferrero E., Low M.G., Silber R., and Goyert S.M. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol. 141 (1988) 547-552
360. Kielian T.L., and Blecha F. CD14 and other recognition molecules for lipopolysaccharide: a review. Immunopharmacology 29 3 (1995) 187-205
361. Rivest S., Nadeau S., Lacroix S., and Laflamme N. Proinflammatory signal transduction pathways in the CNS during systemic immune response. In: Berczi I., Gorczynski R.M., Berczi I., Szentivanyi A., and Series (Eds). Neuroimmune Biology. New Foundation of Biology Volume I (1991), Elsevier 163-173
362. Berczi I., Bertok L., and Bereznay T. Comparative studies on the toxicity of Escherichia coli lipopolysaccharide endotoxin in various animal species. Can J Microbiol 12 (1966) 1070-1071
363. Balm P.H., van Lieshout E., Lokate J., and Wendelaar Bonga S.E. Bacterial lipopolysaccharide (LPS) and interleukin 1 (IL-1) exert multiple physiological effects in the filapia Oreochromis mossambicus (Teleostei). J Comp Physiol [B] 165 (1995) 85-92
364. Levin J., and Bang F.B. The role of endotoxin in the extracellular coagulation of limulus blood. Bull Johns Hopkins Hosp 115 (1964) 265-274
365. Ramachandra R.N., Schon A.H., and Berczi I. Neuro-hormonal host defence in endotoxin shock. Brain Behav Immun 6 (1992) 157-169
366. Parant M., Le Contel C., Parant F., and Chedid L. Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res. 10 (1991) 265-271
367. Zuckerman S.H., Shellhaas J., and Butler L.D. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol. 19 (1989) 301-305
368. Richardson R.P., Rhyne C.D., Fong Y., Hesse D.G., Tracey K.J., Marano M.A., Lowry S.F., Antonacci A.C., and Calvano S.E. Peripheral blood leukocyte kincties following in vivo lipopolysaccharide ILPS) administration to normal human subjects. Influence of elicited hormones and cytokines. Ann Surg. 210 (1989) 239-245
369. Flohe S., Heinrich P.C., Schneider J., Wendel A., and Flohe L. Time course of IL-6 and TNF alpha release during endotoxin-induced endotoxin tolerance in rats. Biochem Pharmacol. 41 (1991) 1607-1614
370. Barber A.E., Coyle S.M., Marano M.A., Fischer E., Calvano S.E., Fong Y., Moldawer L.L., and Lowry S.F. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 150 (1993) 1999-2006
371. Waring P.M., Waring L.J., Billington T., and Metcalf D. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice. Proc Natl Acad Sci U S A 92 (1995) 1337-1341
372. Granowitz E.V., Porat R., Micr J.W., Orencole S.F., Kaplanski G., Lynch E.A., Ye K., Vannier E., Wolff S.M., and Dinarello C.A. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol. 151 (1993) 1637-1645
373. Berg D.J., Kuhn R., Rajewsky K., Muller W., Menon S., Davidson N., Grunig G., and Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 96 (1995) 2339-2347
374. Matic M., and Simon S.R. Effects of gamma interferon on release of tumor necrosis factor alpha from lipopolysaccharide-tolerant huan monocyte-derived macrophages. Infect Immun 60 (1992) 3756-3762
375. Schade F.U., Franke C., Schlegel J., and Rietschel E.T. Formation of a TNF synthesis inhibitor in endotoxin tolerance. Prog Clin Biol Res. 392 (1995) 513-521
376. Henrieson B.E., Neta R., and Vogel S.N. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun 59 (1991) 1188-1191
377. Berezi I., and Nagy I. Neurophormonal control of cytokines during injury. In: Rothwell N.J., and Berkenbosch F. (Eds). Brain Control of Responses to Trauma (1994), Cambridge University Press 32-107
378. Berezi I., and Szentivanyi A. The pituitary gland, psychoneuroimmunology and infections disease. In: Friedman H., Klein T., and Friedman A.L. (Eds). Psychoneuroimmunology, stress and infectious disease (1996), CRC Press, Boca Raton, FL 79-109
379. Wexler B.C., Dolgin A.E., and Tryczynski E.W. Effects of bacterial polysaccharide (Piromen) on the pituitary-adrenal axis: Adrenal ascorbic acid, cholesterol and histological alterations. Endocrinology 61 (1957) 300-308
380. Wilder R.J. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol. 13 (1995) 307-338
381. Torpy D.J., and Chrousos G.P. In: Chikanza I.C. (Ed). Neuroendocrine Immune Mechanisms of Rheumatic Diseases (1996), Bailliere Tindall, Bailliere's Clin Rheumatol London 181-198
382. Berezi I., Chalmers I.M., Nagy E., and Warrington R.J. In: Chikanza I.C. (Ed). Neuroendocrine Immune Mechanisms of Rheumatic Diseases. Bailliere's Clin Rheumatol 10 (1996), Bailliere Tindall, London 227
383. Geller P., Merrill E.R., and Jawetz E. Effects of cortisone and antibiotics on lethal action of endotoxins in mice. Proc Soc Exp Biol Med 86 (1954) 716-719
384. Jansen N.J.G., Vanoeveren W., Hoiting B.H., and Wildevuur C.R.H. Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits. Inflammation 15 (1991) 91-101
385. Izumi T., and Bakhle Y.S. Modification by steroids of pulmonary oedema and prostaglandin E2 pharmacokinetics induced by endotoxin in rats. Brit J Pharmacol 93 (1988) 955-963
386. Yoo J.Y., and Desiderlo S. Innate and acquired immunity intersect in a global view of the acute phase response. Proc Natl Acad Sci U S A 100 (2003) 457-462
387. Cavaillon J.M. The nonspecific nature of endotoxin tolerance. Trends Microbiol. 3 (1995) 320-324
388. Mengozzi M., and Ghezzi P. Cytokine down-regulation in endotoxin tolerance. Eur Cytokine Netw. 4 (1993) 89-98
389. Freudenberg M.A., and Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun. 56 (1988) 1352-1357
390. Evans G.F., and Zuckerman S.H. Glucocorticoid-dependent and-independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol 21 (1991) 973-979
391. Szabo C., Thiemermann C., Wu C.C., Perretti M., and Vane J.R. Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci U S A 91 (1994) 271-275
392. Hansen M.K., Nguyen K.T., Gochler L.E., Gaykema R.P., Fleshner M., Maier S.F., and Watkins I.R. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-ibeta protein in rats. Auton Neurosci 85 (2000) 119-126
393. Mold C., Rodriguez W., Rodic-Polic B., and Du Clos T.W. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fe gamma. J Immunol 169 (2002) 7019-7025
394. Szalai A.J., van Ginkel F.W., Wang Y., McGhee J.R., and Volanakis J.E. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol 165 (2000) 1030-1035
395. Szalai A.J., Nataf S., Hu X.Z., and Barnum S.R. Experimental allergie encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 168 (2002) 5792-5797
396. Galanos C., Freudenberg M.A., and Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A 76 (1979) 5939-5943
397. Kimura T., Itoh N., Takehara M., Oguro I., Ishizaki J.I., Nakanishi T., and Tanaka K. Sensitivity of metallothionein-null mice to LPS/D-galactosamine-induced lethality. Biochem. Biophys Res Commun 280 (2001) 358-362
398. Roth J., Hubschle T., Pehl U., Ross G., and Gerstberger R. Influence of systemic treatment with cyclooxygenase inhibitors on lipopolysaccharide-induced fever and circulating levels of cytokines and cortisol in guinea-pigs. Pflugers Arch 443 (2002) 411-417
399. Fennekohl A., Lucas M., and Puschel G.P. Induction by interleukin 6 of G(s)-coupled prostaglandin E(2) receptors in rat hepatocytes mediating a prostaglandin E(2)-dependent inhibition of the hepatocyte's acute phase response. Hepatology 31 (2000) 1128-1134
400. Streetz K.L., Wustefeld T., Klein C., Manns M.P., and Trautwein C. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 47 (2001) 661-673
401. Shen X., Tian Z., Holtzman M.J., and Gao B. Cross-talk between interleukin Ibeta (IL-Ibeta) and IL-6 signalling pathways: IL-Ibeta selectively inhibits IL-6-activated signal transducer and activator of transcription factor 1 (STAT1) by a proteasome-dependent mechanism. Biochem J 352 Pt 3 (2000) 913-919
402. Jostock T., Mullberg J., Ozbek S., Atreya R., Blinn G., Voltz N., Fischer M., Neurath M.F., and Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268 (2001) 160-167
403. Beigneux A.P., Moser A.H., Shigenaga J.K., Grunfeld C., and Feingold K.R. The acute phase response is associated with retimoid X receptor repression in rodent liver. J Biol Chem 275 (2000) 16390-16399
404. Harris H.W., Gosnell J.E., and Kumwenda Z.L. The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity. J Endotoxin Res 6 (2000) 421-430
405. Fulop A.K., Pocsik E., Brozik M., Karabelyos C., Kiss A., Novak I., Szalai C., Dohozy O., and Falus A. Hepatic regeneration induces transient acute phase reaction: systemic clevation of acute phase reactants and soluble cytokine receptors. Cell Biol Int 25 (2001) 585-592
406. Hecht N., Pappo O., Shouval D., Rose-John S., Galun E., and Axelrod J.H. Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol Ther 3 5 Pt 1 (2001) 683-687
407. Gabay C., Gigley J., Sipe J., Arend W.P., and Fantuzzi G. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur J Immunol 31 (2001) 490-499
408. Carstanjen D., Regenfus M., Muller C., and Salama A. Interleukin-6 is a major effector molecule of short-term G-CSF treatment inducing bone metabolism and an acute-phase response. Exp Hematol 29 (2001) 812-821
409. Suwa T., Hogg J.C., Klut M.E., Hards J., and van Eeden S.F. Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. Am J Respir Crit Care Med 163 (2001) 970-976
410. Beishuizen A., Thijs L.G., Haanen C., and Vermes I. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86 (2001) 2811-2816
411. Previte J.J., Chang Y., and El-Bisi H.M. Detoxification of Salmonella typhimurium lipopolysaccharide by ionizing radiation. J Bacteriol 93 (1967) 1607
412. Fust G., Bertok L., and Juhasz-Nagy S. Interactions of radio-detoxifield Escherichia coli endotoxin preparations with the complement system. Infect Immun. 16 (1977) 26-31
413. Bertok L. Stimulation of nonspecific resistance by radiation-detoxified endotoxin. In: Nowotny A. (Ed). Beneficial Effects of Endotoxin (1983), Plenum Press, New York 213-226
414. Banhegyi D., Varnai F., Horyath A., and Bertok L. Treatment of severe immune deficiency with radio-detoxified endotoxin. J Med. 23 (1992) 154-156
415. Gustafson G.L., Rhodes M.J., and Hegel T. Monophosphoryl lipid A as a prophylactice for sepsis and septic shock. Prog Clin Biol Res 392 (1995) 567-579
416. Astiz M.E., Rackow E.C., Still J.G., Howell S.T., Cato Á., Von Eschen K.B., Ulrich J.T., Rudbach J.A., McMahon G., Vargas R., et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med 23 (1995) 9-17
417. Jamieson J.C., Lammers G., Janzen R., and Woloski B.M.R.N.J. The acute phase response to inflammation: The role of monokines in changes in liver glycoproteins and enzymes of glycoprotein metabolism. Comp Biochem Physiol 87B (1987) 11-15
418. Berezi I. Neurochormonal immunoregulation. Endocr Pathol 1 (1990) 197-219
419. Spangelo B.L., and Macleod R.M. Immunopeptide regulation of anterior pituitary function. Int J Neurosci 51 (1990) 369-370
420. Akira S., and Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 127 (1992) 26-50
421. Baue A.F. Neuroendocrine response to severe trauma and sepsis. In: Faist E., Ninnemann J., and Green D. (Eds). Immune consequences of trauma, shock and sepsis (1989), Springer Verlag 17-32
422. Bornstein S.R., Licinio J., Tauchnitz R., Engelman L., Negrao A.B., Gold P., and Chrousos G.P. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab 83 (1998) 280-283
423. Kolb-Bachofen V. A review on the biological properties of C-reactive protein. Immunobiology 183 (1991) 133-145
424. Ballou S.P., and Kushner I. C-reactive protein and the acute phase response. Adv Intern Med. 37 (1992) 313-336
425. Young B., Gleeson M., and Cripps A.W. C-reactive protein: a critical review. Pathology 23 (1991) 118-124
426. Mold C., Nakayama S., Holzer T.J., Gewurz H., and Du Clos T.W. C-reactive protein is protective against Streptococcus pneumoniac infection in mice. J Exp Med 154 (1981) 1703-1708
427. Vogeser M., Zachoval R., Felbinger T.W., and Jacob K. Increased ratio of serum cortisol to cortisone in acute-phase response. Horm Res 58 (2002) 172-175
428. Bauer J., Birmelin M., Northoff G.H., Northemann W., Tran-Thi T.A., Ueberberg H., Decker K., and Heinrich P. Induction of rat β2-macroglobulin in vivo and in heaptocyte primary cultures: synergistic action of glucocorticoids and a Kupffer cell derived factor. FEBS Lett 177 (1984) 89-94
429. van Gool J., Boers W., Sala M., and Ladiges N.C. Glucocorticoids and catecholamines as mediators of acute-phase proteins, especially rat alpha-macrofoetoprotein. Biochem J 220 (1984) 125-132
430. Wassell J. Haptoglobin: function and polymorphism. Clin Lab 46 11-12 (2000) 547-552
431. Dacmen M.A., Heemskerk V.H., van't Veer C., Denecker G., Wolfs T.G., Vandenabeele P., and Buurman W.A. Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 102 (2000) 1420-1426
432. Liu H., Jensen L., Hansen S., Petersen S.V., Takahashi K., Ezekowitz A.B., Hansen F.D., Jensenius J.C., and Thiel S. Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. Scand J Immunol 53 (2001) 489-497
433. Turner M.W., and Hamvas R.M. Mannose-birding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2 (2000) 305-322
434. Van Gool J., Van Vugt H., Helle M., and Aarden L.A. The relation among stress, adrenalin, interleukin 6, and acute phase proteins in the rat. Clin Immunol Immunopathol 57 (1990) 200-210
435. Takala J., Ruokonen E., Webster N.R., et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341 (1999) 785-792
436. Jaschke M.G., Herndon D.N., Wolf S.E., et al. Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats. J Surg Res 83 (1999) 122-129
437. Derfalvi B., Igaz P., Fulop K.A., Szalai C., and Falus A. Interleukin-6-induced production of type II acute phase proteins and expression of junB gene are downregulated by human recombinant growth hormone in vitro. Cell Biol Int 24 (2003) 109-114
438. Berczi I., Nagy E., Esa S.L., and Kovacs K. Pituitary hormones and contact sensitivity in rats. Allergy 38 (1983) 325-330
439. Berczi I., Nagy E., Asa S.L., and Kovacs K. The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum 27 (1984) 682-688
440. Ramirez R.J., Wolf S.E., and Herndon D.N. Is there a role for growth hormone in the clinical management of burn injuries?. Growth Horm IGF Res 8 Suppl B (1998) 99-105
441. Jaschke M.G., Barrow R.E., and Herndon D.N. Recombinant human growth hormone treatment in pediatric burn patients and its role during the hepatic acute phase response. Crit Care Med 28 (2000) 1578-1584
442. Jaschke M.G., Herndon D.N., and Barrow R.E. Insulin-like growth factor I in combination with insulin-like growth factor binding protein 3 affects the hepatic acute phase response and hepatic morphology in thermally injured rats. Ann Surg 231 (2000) 408-416
443. Jeschke M.G., Barrow R.E., and Herndon D.N. Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg 231 (2000) 246-252
444. Basoglu M., Kiziltunc A., Yildirgan M.I., Gumustekin K., Gumus M., Yildirim A., and Atamanalp S.S. Recombinant human growth hormone modulates the hepatic acute-phase response and P-selectin in burned rats. Burns 28 (2002) 760-764
445. Kotler D.P. Cachexia. Ann Intern Med 133 (2000) 622-634
446. Langhans W. Anorexia of infection: current prospects. Nutrition 16 (2000) 996-1005
447. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 2 (2000) 209-214
448. Kushner I. C-reactive protein elevation can be caused by conditions other than inflammationand may reflect biologic aging. Cleve Clin J Med 68 (2001) 535-537
449. Bruunsgaard H., Pedersen M., and Pedersen B.K. Aging and proinflammatory cytokines. curr Opin Hematol 8 (2001) 131-136
450. Duncan B.B., and Schmidt M.I. Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 119 (2001) 122-127
451. Richardson A.P., and Tayek J.A. Type 2 diabetic patients may have a mild form of an injury response: a clinical research center study. Am J Physiol Endocrinol Metab (2002) E1286-E1290
452. Fernandez-Real J.M., Vayreda M., Richart C., Gutierrez C., Broch M., Vendrell J., and Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86 (2001) 1154-1159
453. Arnalich F., Hernanz A., Lopez-Maderuelo D., Pena J.M., Camacho J., Madero R., Vazquez J.J., and Montiel C. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res 32 (2000) 407-412
454. Pickup J.C., Chusney G.D., Thomas S.M., and Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67 (2000) 291-300
455. Fernandez-Real J.M., Broch M., Vendrell J., Gutierrez C., Casamitjana R., Pugeat M., Richart C., and Ricart W. Interleukin-6 gene polynorphism and insulin sensitivity. Diabetes 49 (2000) 517-520
456. Boss B., and Neeck G. Correlation of IL-6 with the classical humoral disease activity parameters ESR and CRP and with serum cortisol, reflecting the activity of the HPA axis in active rheumatoid arthritis. Z Rheumatol 59 Suppl 2 (2000) II/62-II/64
457. Sakane T., and Suzuki N. Neuro-endocrine-immune axis in human rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 48 (2000) 417-427
458. O'Hara R., Murphy E.P., Whitehead A.S., FitzGerald O., and Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2 2 (2000) 142-144
459. Janssen U., Bahlmann F., Kohl J., Zwirner J., Haubitz M., and Floege J. Activation of the acute phase response and complement C3 in patients with IgA nephropathy. Am J Kidney Dis 35 (2000) 21-28
460. Anisman H., Baines M.G., Berezil J., et al. Neuroimmune mechanisms in health and disease: 1. Health. Can Med Assoc J 155 (1996) 867-874
461. Anisman H., Baines M.G., Berczi I., et al. Neuroimmune mechanisms in health and disease: 2. Disease. Can Med Assoc J 155 (1996) 1075-1082
462. Banck G., and Forsgren A. Many bacterial species are mitogenic for human blood B lymphocytes. Scand J Immunol. 8 (1978) 347-354
463. Fleischer B., Gerlach D., Fuhrmann A., and Schmidt K.H. Superantigens and pseudosuperantigens of gram-positive cocci. Med Microbiol Immunol (Berl) 184 (1995) 1-8
464. Levinson A.I., Kozlowski L., Zheng Y., and Wheatley L. B-cell superantigens: definition and potential impact on the immune response. J Clin Immunol. 15 6 Suppl (1995) 26S-36S
465. Zumla A. Superantigens, T cells and microbes. Clin Infect Dis 15 (1992) 313-320
466. Kotb M. Bacterial pyrogenic exotoxins as superatigens. Clin Microbiol Rev. 8 (1995) 411-426
467. Spangelo B.L., deHoll P.D., Kalabay L., Bond B.R., and Arnaud P. Neurointermediate pituitary lobe cells synthesize and release interleukin-6 in vitro: effects of lipopolysaccharide and interleukin-1 beta. Endocrinology 135 (1994) 556-563
468. Chao H.S., Poisner A.M., Poisner R., and Handwerger S. Lipopolysaccharides inhibit prolactin and renin release from human decidual cells. Biol Reprod. 50 (1994) 210-214
469. Di Santo E., Sironi M., Pozzi P., Gnocchi P., Isetta A.M., Delvaux A., Goldman M., Marchant A., and Ghezzi P. Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin-1 beta production in the brain without affecting the activation of the hypothalamus-pituitary-adrenal axis. Neuroimmunomodulation 2 (1995) 149-154
470. Faggioni R., Fantuzzi G., Villa P., Buurman W., van Tits L.J., and Ghezzi P. Independent down-regulation of central and peripheral tumor necrosis lactor production as a result of lipopolysaccharide tolerance in mice. Infect Immun. 63 (1995) 1473-1477
471. Das K.P., McMillian M.K., Bing G., and Hong J.S. Modulatory effects of [Met5]-enkephalin on interleukin-I beta secretion from microglia in mixed brain cell cultures. J Neuroimmunol. 62 (1995) 9-17
472. Scotte M., Hiron M., Masson S., Lyoumi S., Banine F., Teniere P., Lebreton J.P., and Daveau M. Differential expression of cytokine genes in monocytes, peritoneal macrophages and liver following endotoxin-or turpentine-induced inflammation in rat. Cytokine 8 (1996) 115-120
473. Gaykema R.P., Dijkstra I., and Tilders F.J. Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion. Endocrinology 136 (1995) 4717-4720
474. (5 Pt 2). Laye S., Bluthe R.M., Kent S., Combe C., Medina C., Parnet P., Kelley K., and Dantzer R. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS. Am J Physiol. 268 (1995) R1327-R1331
475. Berezi I., Bertok L., Baintner Jr. K., and Veress B. Failure of oral Escherichia coli endotoxin to induce either specific tolerance or toxic syndromes in rats. J Path Bact 96 (1968) 481-486
476. Kocsar L.T., Bertok L., and Varteresz V. Effect of bile acids on the intestinal absorption of endotoxin in rats. J Bacteriol. 100 (1969) 220-223
477. Mimura Y., Sakisaka S., Harada M., Sata M., and Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology 109 (1995) 1969-1976
478. Bertok L. Physico-chemical defence of vertebrate organisms: the role of bile acids in defence against endotoxins. Persp Biol Med 21 (1977) 70-76